Suggested Readings

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.   

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.  

Drug database: emtricitabine/tenofovir alafenamide.

Drug database: emtricitabine/tenofovir disoproxil fumarate.

Drug database: cabotegravir.

Being PrEPared—preexposure prophylaxis and HIV disparities.

Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.    

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, et al; iPrEx Study Team. N Engl J Med. 2010;363(27):2587-2599.

Lifetime risk of a diagnosis of HIV infection in the United States.

Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.

Cabotegravir for HIV prevention in cisgender men and transgender women.

Landovitz RJ, et al; HPTN 083 Study Team. N Engl J Med. 2021;385(7):595-608.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Mayer KH, et al. Lancet. 2020;396(10246):239-254.  

Clinical Commissioning Policy. Reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV.

National Health Service. 2020.  

How to incorporate HIV PrEP into your practice.

Stewart J, Stekler JD. J Fam Pract. 2019;68(5):254-261.   


Patient and provider assistance:

Information about preexposure prophylaxis (PrEP), nonoccupational postexposure prophylaxis (nPEP), insurance and insurance rights, finding a PrEP/nPEP provider, and a list of PrEP resources by state.

Provider assistance: AIDS Education and Training Center (AETC)

National Coordinating Resource Center Supports national HIV priorities by providing training, consultation, and resources

Ready, Set, PrEP! provides free PrEP HIV-prevention medication

Clinic visits and lab tests vary depending on income If PrEP medication is a good option for your clients, they can choose the application process that is most convenient. By phone: 855-447-8410

Patient assistance (without insurance)

The PrEP patient assistance program will provide medication at no cost for those who meet income guidelines

Uninsured 24/7 support online, by phone during business hours, and fax enrollment

Co-pay assistance (for patients with nongovernment insurance)

Phone number: 877-505-6986 

Co-pay assistance/out-of-pocket costs: ViiV Connect


PrEParing to End the Epidemic: Optimizing HIV Prevention in Primary Care

This educational program will focus on how to identify and engage with patients at high risk for HIV infection, use nonjudgmental communication skills to remove the stigma associated with HIV, and foster meaningful discussions about sexual health and behavior. It will also provide practical clinical information on implementing PrEP services in primary care practice, including the safety and efficacy of oral and long-acting injectable PrEP agents, initiating and monitoring patients on PrEP, and using shared decision-making to address patient preferences and priorities for HIV prevention.

BRIDGE PrEP: Building Bridges to Reach People Who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

This initiative aims to educate and motivate clinicians and other providers working in substance use disorder (SUD) centers in metropolitan and less-populated areas to increase their clients’ awareness of and access to HIV preexposure prophylaxis (PrEP). This program will offer medical and addiction-services specialists’ leading-edge methods to collaboratively reach people who inject drugs (PWID) and connect them to providers for HIV testing and PrEP services.

The HIV Journey Staying the Course Through Critical Junctions in Care

HIV is a life-long condition that is becoming increasingly complex. Clinicians must be prepared to face myriad situations over a patient’s lifespan, relating both to their HIV and to either other comorbidities or issues such as stigma or social determinants of health. In this interactive activity, you will follow a patient diagnosed as an adolescent through his lifespan with HIV to make decisions about common challenges. Dr. Onyema Ogbuagu will review rapid ART, educating adolescents, addressing nonadherence due to challenges in social determinants of health, implicit bias, long-acting injectables, virologic failure, switching ART regimens, 2-drug regimens, common comorbidities in aging patients, and drug-drug interactions, all placed in the context of important mile markers along a patient’s HIV journey.

Linked Resources


Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update. A clinical practice guideline.

Centers for Disease Control and Prevention.

Sexually transmitted infections treatment guidelines, 2021.

Centers for Disease Control and Prevention.

Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016.

CDC Stacks. Centers for Disease Control and Prevention. 

The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health. 2nd ed.

Makadon H, et al; American College of Physicians, eds. Boston, MA: Fenway Health; 2015.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society—USA Panel.

Saag MS, et al. JAMA. 2020;324(16):1651-1669.



HIV Prevention Certified Provider™ Certification Program.

American Academy of HIV Medicine.

Basic statistics.

Centers for Disease Control and Prevention.

National Clinician Consultation Center.

University of California, San Francisco. 

HIV drug interactions.

University of Liverpool.


Related activities
1.00 CME/CE

The PrEP Journey

Charting the Course Through HIV Prevention

Faculty: Shauna Applin, A-NP, AAHIVs; Daniel Richardson, FRCP, FAChSHM
Release: 07/31/2023
Expiration: 07/31/2024